U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H28O6
Molecular Weight 400.4648
Optical Activity ( + / - )
Defined Stereocenters 4 / 4
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of ENPROSTIL

SMILES

COC(=O)CCC=C=CC[C@H]1[C@H](\C=C\[C@H](O)COC2=CC=CC=C2)[C@@H](O)CC1=O

InChI

InChIKey=PTOJVMZPWPAXER-FPXSIRDUSA-N
InChI=1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H28O6
Molecular Weight 400.4648
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 3
Optical Activity UNSPECIFIED

Description

Enprostil, a derivative of heptadienoic acid, is a prostaglandin E2 agonist. It is effective in the treatment of patients with duodenal or gastric ulcers.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
12.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Camleed

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
As evidenced by a few controlled trials in patients with gastric ulcers, treatment with enprostil 35 micrograms twice daily for 6 weeks provides ulcer healing in parallel with pain relief as effectively as cimetidine and ranitidine in a high percentage of patients (about 80% after 6 weeks).
Route of Administration: Oral
In Vitro Use Guide
The concentration of enprostil inducing a half maximal contraction of smooth muscle strips from the circular layer of dog colon(EC50) was 400 nM and the maximal effect was obtained at 1 uM.
Substance Class Chemical
Record UNII
J4IP5Z9DAU
Record Status Validated (UNII)
Record Version